Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


MET Alterations: Mastering the Features of and Testing for a New Target in NSCLC (35 mins)
  • CME

Watch this expert overview of MET gene alterations in NSCLC, including guidance on testing for targetable METex14-skipping mutations.
D. Ross Camidge, MD, PhD
Luis Paz-Ares, MD, PhD
Karen L. Reckamp, MD, MS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: July 24, 2020 Expiration: July 23, 2021

This program is divided into short segments that you can review from the Activity landing page.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the rationale for METex14 as a targetable alteration in NSCLC
  • Evaluate the available testing platforms and use of tissue and plasma biopsies to assess METex14 in patients with NSCLC
  • Discuss the available clinical evidence for selective MET inhibitors in METex14-altered NSCLC, including an assessment of relative efficacy and central nervous system responses
  • Appropriately manage treatment-related adverse events associated with MET targeted agents used in patients with advanced-stage NSCLC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


D. Ross Camidge, MD, PhD

Professor of Medicine/Oncology
University of Colorado Cancer Center
Aurora, Colorado

D. Ross Camidge, MD, PhD, has disclosed that he has received consulting fees from 14ner Oncology, AbbVie, Achilles, Apollomics, Archer, BeyondSpring, Biothera, Blueprint, Bristol-Myers Squibb, CBT Pharmaceuticals, Daiichi Sankyo, EMD Serono, G1 Therapeutics, Helssin, Lilly, Medtronic, Ribon, and Takeda and funds for research support paid to his institution from AbbVie, AstraZeneca, Bristol-Myers Squibb, Hansoh, Lycera, Medimmune, Merck, Pfizer, Phosplatin, Roche/Genentech, Seattle Genetics, Symphogen, and Takeda.
Luis Paz-Ares, MD, PhD

Medical Oncology
University Hospital Doce de Octubre
Madrid, Spain

Luis Paz-Ares, MD, PhD, has disclosed that he has received honoraria from AstraZeneca, Bristol-Myers Squibb, Lilly, MSD, Novartis, Pfizer, and Roche.
Karen L. Reckamp, MD, MS

Professor of Medicine
, Division of Medical Oncology
Department of Medicine
Cedars Sinai
Los Angeles, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, Calithera, Genentech, Guardant, Precision Health, and Tesaro and funds for research support paid to her prior institution from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno.


Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with MET-altered NSCLC.


This program is intended for global medical oncologists, pulmonologists, and other healthcare providers who care for patients with NSCLC.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 24, 2020, through July 23, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Gain key clinical insights fast with this short slideset from CCO on RET fusion–positive NSCLC

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Latest evidence on effective management of chronic lymphocytic leukemia (CLL) using BTK inhibitors in this video from Clinical Care Options (CCO)

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 16, 2020 Expired: September 15, 2021

Commentary from Elizabeth R. Plimack, MD, MS on new treatment options, including erdafitinib and enfortumab vedotin, for urothelial cancer from CCO

Elizabeth R. Plimack, MD, MS Released: September 15, 2020

From Clinical Care Options (CCO), expert commentary by Dr Richard Finn on the use of atezolizumab plus bevacizumab for advanced HCC

Richard Finn, MD Released: September 15, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?